07:00 , Apr 3, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Musculoskeletal disease Calcium release-activated calcium channel (CRAC); stromal interaction molecule 1 (STIM1); transmembrane protein 142A (ORAI1; TMEM142A; CRACM1) In vitro and genetic studies suggest...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

CalciMedica management update

CalciMedica Inc. , La Jolla, Calif.   Business: Autoimmune, Inflammation   Hired: Michael Dunn as SVP of corporate development, formerly SVP of corporate development at Biocept Inc.  ...
07:00 , Aug 15, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Pancreatitis Calcium release-activated calcium channel (CRAC) Cell culture studies suggest antagonizing CRAC could help treat acute pancreatitis. In a pancreatic acinar cell model of...
07:00 , Aug 8, 2013 |  BC Innovations  |  Targets & Mechanisms

CRACking pancreatitis

The handful of companies pursuing CRAC inhibitors for immunological disorders have a new indication to consider-acute pancreatitis. New findings from Cardiff University 1 show that the target plays a central role in the painful and...
08:00 , Feb 21, 2011 |  BC Week In Review  |  Clinical News

CM2489: Phase I started

CalciMedica began a blinded, placebo-controlled, U.S. Phase I trial evaluating single ascending-doses of daily oral cm 2489 in 48 healthy volunteers. CalciMedica Inc. , La Jolla, Calif.   Product: cm 2489   Business: Autoimmune  ...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Company News

CalciMedica, TorreyPines deal

CalciMedica exercised an option under a 2007 deal with TorreyPines to acquire IP related to the use of stromal interaction molecule-1 (STIM-1) and Ca release-activated Ca ( CRAC ) channel inhibitors to treat CNS disorders....
08:00 , Dec 10, 2007 |  BioCentury  |  Emerging Company Profile

CalciMedica: CRACking toxicity

Calcineurin inhibitors are effective in preventing acute organ transplant rejection and treating autoimmune diseases, but their long-term use is associated with renal and hepatic toxicities. CalciMedica Inc. hopes to sidestep these toxicities by developing therapeutics...
08:00 , Dec 10, 2007 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Corporate Profile CalciMedica Inc. La Jolla, Calif. Technology: Inhibition of calcium release-activated calcium (CRAC) channels Disease focus: Transplant, autoimmune Clinical status: Lead optimization Founded: 2006 by Gonul Velicelebi, Ken Stauderman and Jack Roos University collaborators:...
07:00 , May 14, 2007 |  BC Week In Review  |  Company News

CalciMedica, TorreyPines, CBR Institute for Biomedical Research deal

CalciMedica purchased TPTX's patent application covering uses of stromal interaction molecule-1 (STIM-1) for regulating Ca release-activated Ca ( CRAC ) channels. CalciMedica also obtained NGX53187 and other preclinical compounds that inhibit CRAC channels and block...